Categories Earnings, Health Care

CorMedix (NYSE: CRMD): Q4 2019 Earnings Snapshot

— CorMedix Inc. (NYSE: CRMD) reported a fourth-quarter 2019 loss of $0.21 per share versus a loss of $0.24 per share expected.

— The latest quarter’s loss was compared to the prior-year quarter’s profit of $0.10 per share. This was due to the reversal of clinical trial expenses as a result of the settlement agreement with its CRO in 2018.

Earnings Update by AlphaStreet

— Net sales fell by 7% year-over-year to $25 thousand versus $90 thousand expected.

— The company has begun the submission process of the New Drug Application (NDA) for Neutrolin for the prevention of catheter-related bloodstream infections in hemodialysis patients.

— The company believes it is on schedule for potential approval of the NDA for use in adult hemodialysis patients during the second half of 2020.

— CorMedix has been approved to transfer about $5.5 million of the total $6 million of its available tax benefits to an unrelated, profitable New Jersey corporation for about $5.2 million in net proceeds.

— Total cash on hand and short-term investments as of December 31, 2019, amounted to $28.3 million, excluding restricted cash of $0.2 million.

— The company believes it has sufficient resources to fund operations into the second quarter of 2021, including the submission of the NDA for Neutrolin and initial preparations for commercial launch.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Infographic: How Macy’s (M) performed in Q4 2023 financial results

Macy’s, Inc. (NYSE: M) reported fourth quarter 2023 earnings results today. Net sales were $8.1 billion, down 1.7% versus the same period a year ago. Total revenue dropped to $8.37

AZO Earnings: AutoZone’s Q2 2024 earnings rise on higher sales

AutoZone, Inc. (NYSE: AZO) announced financial results for the second quarter of 2024, reporting higher sales and net profit. The company had a total of 7,191 stores open at the end

SJM Earnings: Key quarterly highlights from J.M. Smucker’s Q3 2024 financial results

The J.M. Smucker Co. (NYSE: SJM) reported third quarter 2024 earnings results today. Net sales increased 1% year-over-year to $2.23 billion. Comparable sales increased 6%. Net income decreased 42% to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top